The metabolic toxicities of antiretroviral therapy

International Journal of STD and AIDS

Volumn 12, Issue 9, 2001, Pages 555-564

  Herman, J S ^a   Easterbrook, P J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiretrovirals; Bone density abnormalities; Fat redistribution syndrome; Hyperlipidaemia; Lipodystrophy; Mitochondrial toxicity

Indexed keywords

ANTIRETROVIRUS AGENT;

ANEMIA; BONE NECROSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPOHYPERTROPHY; MYOPATHY; NEUROPATHY; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES, METABOLIC; DNA, MITOCHONDRIAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; LIPODYSTROPHY; METABOLIC DISEASES; MITOCHONDRIA; OSTEONECROSIS;

EID: 0034860469     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011923714     Document Type: Review

References (71)

1. Protease inhibitors for HIV infection
2. HIV-1 protease inhibitors
3. Report of the NIH panel to define principles of therapy of HIV infection
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
6. Relative influences of sex, race, environment, and HIV infection on body composition in adults
7. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
8. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
9. Indinavir-associated lipodystrophy
10. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
11. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
12. 'Buffalo hump' in men with HIV-1 infection
13. Visceral abdominal fat accumulation associated with use of indinavir
14. Hypertriglyceridaemia in the acquired immunodeficiency syndrome
15. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
16. Lipid evaluation and glucose metabolism in HIV-1 positive patients treated with protease inhibitors
17. Severe premature coronary artery disease with protease inhibitors
18. Vascular complications associated with use of HIV protease inhibitors
19. Vascular complications associated with use of HIV protease inhibitors
20. Myocardial infarction incidence in clinical trials of 4 protease inhibitors
21. Cardiovascular complications of HAART: Need for perspective
22. Fasting hyperinsulinaemia and changes in regional body composition in human immunodeficiency virus-infected women
23. Reports of diabetes and hyperglycaemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV)
24. Protease inhibitor-associated hyperglycaemia
25. New-onset diabetes mellitus associated with use of protease inhibitor
26. Incidence, characteristics and prognosis of diabetes mellitus associated with protease inhibitors
27. HIV protease-induced lipodystrophy syndrome
28. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
29. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
30. Indinavir enhances retinoic acid signalling: Nelfinavir, saquinavir and ritonavir inhibit retinoid effects in vitro
31. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as the common pathway
32. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
33. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
34. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
35. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
36. Atorvostatin and gemfibrozil for protease inhibitor-related lipid abnormalities
37. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART
38. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant growth hormone
39. Liposuction for protease inhibitor-associated lipodystrophy
40. Reversion of metabolic abnormalties after switching from HIV-1 protease inhibitors to nevirapine
41. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz
42. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz
43. Protease inhibitor class-sparing maintenance therapy with abacavir (ABC)+lamivudine (3TC)+zidovudine (ZDV) in patients with long-term suppression of HIV-1 RNA
44. The other human genome: Mitochondrial DNA and disease
45. Diseases of the mitochondrial DNA
46. Mitochondrial toxicity of antiviral drugs
47. Severe toxicity of fialuridine (FIAU)
48. Fulminant hepatic failure associated with 2′-3′-dideoxyinosine (ddI)
49. Adverse effects of antiretroviral therapy
50. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
51. Fulminant hepatitis with severe lactic acidosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy
52. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
53. Mitochondrial myopathy caused by long-term zidovudine toxicity
54. Depletion of muscle mitochondria DNA in AIDS patients with zidovudine-induced myopathy
55. Zidovudine: Five years later
56. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection
57. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
58. Safety of adefovir dipivoxil in the treatment of HIV infection
59. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management
60. Rates and risk factors for adverse events associated with didanosine in the expanded access programme
61. Hyperlactaemia and antiretroviral therapy in the Swiss HIV Cohort Study
62. Lactic acidosis
63. Differences in anion gap with different nucloside RTI combinations
64. Riboflavin to treat nucleoside analogue-induced lactic acidosis
65. Riboflavine and severe lactic acidosis
66. Osteopenia in a randomized, multicentre study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well-controlled HIV viraemia
67. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
68. Protease inhibitors inhibit in vitro conversion of 25 (OH)-vitamin D
69. HAART-associated osteopenia is caused by oxidised lipoproteins: A hypothesis
70. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis